UNIGE document Scientific Article
previous document  unige:155766  next document
add to browser collection
Title

Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists

Authors
Glatzer, Markus
Leskow, Pawel
Elicin, Olgun
Furrer, Markus
Gambazzi, Franco
Dutly, André
Gelpke, Hans
show hidden authors show all authors [1 - 26]
Published in Translational lung cancer research. 2021, vol. 10, no. 4, p. 1960-1968
Abstract Stage III N2 non-small cell lung cancer (NSCLC) is a very heterogeneous disease associated with a poor prognosis. A number of therapeutic options are available for patients with Stage III N2 NSCLC, including surgery [with neoadjuvant or adjuvant chemotherapy (CTx)/neoadjuvant chemoradiotherapy (CRT)] or CRT potentially followed by adjuvant immunotherapy. We have no clear evidence demonstrating a significant survival benefit for either of these approaches, the selection between treatments is not always straightforward and can come down to physician and patient preference. The very heterogeneous definition of resectability of N2 disease makes the decision-making process even more complex.
Keywords Non-small cell lung cancer (NSCLC)Decision-makingRadiotherapyStage III N2 lung cancerSurgery
Identifiers
PMID: 34012806
Full text
Structures
Research group Cancer du poumon et mésothéliome pleural malin (944)
Citation
(ISO format)
GLATZER, Markus et al. Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists. In: Translational lung cancer research, 2021, vol. 10, n° 4, p. 1960-1968. doi: 10.21037/tlcr-20-1210 https://archive-ouverte.unige.ch/unige:155766

55 hits

19 downloads

Update

Deposited on : 2021-10-28

Export document
Format :
Citation style :